Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab and capecitabine in resected cholangiocarcinoma
NCT05207735Phase 2Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- Jan 2022
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label trial of sintilimab in cholangiocarcinoma (CCA), sponsored by Henan Cancer Hospital. Primary endpoint: 2-year recurrence-free survival rate. Status: unknown.
02
Drugs
sintilimab
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT05207735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05207735.